CRDF Cardiff Oncology Inc

$CRDF Next targets are gaps ,90 then 2,84 when the last collapse started end of january,the day of Erlander resignation. The legal thing has been closed as Logic suggested,no Surprise as I have Always said. Now Let's focus on ovansertib. The benefits of this product are Still not fully understood in This board, I am expecting more news soon. Strong buy.

$CRDF MINUTE ORDER for proceedings held before Magistrate Judge Jill L. Burkhardt: Status Conference and Case Management Conference ("CMC") held on 9/11/2026. Status Conference and CMC continued to 9/16/2026, at 12:30 PM before Magistrate Judge Jill L. Burkhardt. The CMC and Status Conference will be held by ZoomGov video conference. (Plaintiff Attorney: Kourtney Merrill, Jeffrey Fessler, Bradley Graveline). (Defendant Attorney: Deborah Fishman, Abigail Struthers). (nxo.) (Entered on 09/11/2026.) It appears discussions are ongoing. Additional conference scheduled for Wednesday. Hopefully, we're in the home stretch.

$CRDF Merck needs onvansertib for bevacizumab synergy + GI expansion. AZ needs onvansertib for RAS/MAPK pathway alignment + ADC synergy. BMS needs onvansertib for GI oncology dominance + durability. Pfizer needs onvansertib for ADC resistance reversal. Amgen needs onvansertib for RAS franchise protection. Lilly needs onvansertib for pathway architecture + combination logic. Gilead needs onvansertib for ADC synergy + GI oncology expansion. Novartis needs onvansertib for synthetic‑lethal pathway fit + precision oncology expansion. Takeda needs onvansertib for GI oncology specialization + first‑line CRC expansion. BeiGene needs onvansertib for global GI expansion + combination‑friendly mechanism. Roche/Genentech needs onvansertib for bevacizumab‑owner synergy + RAS‑pathway expansion. Sanofi needs onvansertib for ADC synergy + oncology franchise rebuilding. J&J needs onvansertib for resistance‑reversal strategy + ADC combination potential.

$CRDF New Joint Filing Both sides filed a joint motion tonight asking the court to slow down CRDF's motion to dismiss NMS’s amended counterclaims. They cite the ENEs, the August status conference, and the September 11 follow-up, and they say they need time to “finalize” those discussions. They did not pause NMS’s already-briefed motion to dismiss two of Cardiff’s extra-contractual counts. They did reserved every claim and defense, so this is not a walk-away but they very much appear to be working toward a full settlement. Bottom line: Lawyers do not jointly stop briefing unless a deal is live enough that writing the next brief feels like wasted money. Still not a signed settlement but another very encouraging signal.

$CRDF The stock should gap up significantly on this news. The market has been pricing in a ~50% probability of total loss, and the opposite happened. So the risk is now gone. The remaining risks (Phase 3 execution, financing, commercialization) are standard biotech risks — and with practice-changing Phase 2 data and an FDA-aligned registrational program, Cardiff is now one of the most attractive Phase 3 oncology assets available. Cardiff could now focus on BD/ partnership and funding for start of phase 3 in Q1 2027!

$CRDF I am reasonably certain that with the board seat and the statement made by Nerviano in the press release, there is going to be an effort to enroll and conduct P3 at warp speed to get data as fast as possible.

$CRDF Couple conferences on deck this month - ✅ SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc.(CRDF) , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8 th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesday, September 8 at 9:00 AM ET Also - H.C. Wainwright 28 th Annual Global Investment Conference Fireside Chat; Monday, September 14 at 10:00 AM ET

$CRDF Mani (Cardiff) was the first speaker presentation to open the three day Ras conference today, that seems significant to me. Much better than presenting at 4 pm on the third and final day!

$CRDF Have been holding a heavy bag here for years. Added a little big today to celebrate! 😂

$CRDF There is an attorney only case management conf on 9/11 at 1230 PST. My guess is that they will arrive at a new milestone/settlement today because they have to report tomorrow (per the order of 8/31) especially since the judge set it during noon hour.

$CRDF We need volume and industry awareness back. Once this get resolved Mani cannot fall back into the old playbook of just going to small conferences. She needs to make a big splash. I fear our new boutique PR firm is to inexperienced in this regard.

$CRDF All the Bears and Board Trash (BT) have gone, covered at 80 cents . . . OR I have blocked them all . . . 🤠

$CRDF Once the Law suit is resolved, and have the phase III ready asset with approved FDA stamp, they raise at 6 bucks per share or higher.

$CRDF Onvansertib has an addressable market of $10B in the US alone. That makes it one of the most valuable oncology drugs in development at the moment. There is zero chance that phase 3 doesn’t get funded. Get your head out of the sand and buy this at a price today that you’ll look back in disbelief.

$CRDF the short squeeze is now in effect. The settlement resolved all license uncertainty and both parties joined forces to advance this to Phase 3. Only uncertainty now is the funding of the trial, but thats going to solve on its own. Timing of onvansertib aligns will with massive upcoming LOEs and a phase 3 ready asset like this is a no brainer. Pressure now on big pharma on whom makes the best offer

$CRDF big week for crdf Tomorrow ras summit Friday legal update Following monday investor conference

$CRDF There is an interesting timing setup: Friday, Sept. 11 → Court/status conference ↓ Weekend → Potential settlement agreement ↓ Monday, Sept. 14 → H.C. Wainwright fireside chat So if Cardiff announces a favorable settlement on Friday evening or over the weekend, Monday's investor event would give management a natural opportunity to discuss the implications with investors.

$CRDF Some people start to think in a rational way finally. This Is the most undervalued stock in the biotech space.Strong buy

$CRDF This is the most important part of the press release. In my mind I think that NMS is going to be very active in recruiting patients. Keep in mind one of their biggest complaints in the lawsuit was how long this was taking and the strategy that Cardiff was taking in getting this drug to the finish line. “We look forward to working with Cardiff to advance onvansertib into a global Phase 3 study in first-line RAS-mutated metastatic colorectal cancer and to bring this therapy to patients,” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS Group S.r.l.

$CRDF This Is a gradual repricing rather than a short squeeze, under 1$ It was Indeed ridiculous. Considering the pipeline Advance and the last news should be worth about 4$ now. A serious partnership to support pH.3 would produce a massive gap up,and then you would see a real squeeze. 🍀